Published in CA Cancer J Clin on August 19, 2011
A systematic comparison and evaluation of high density exon arrays and RNA-seq technology used to unravel the peripheral blood transcriptome of sickle cell disease. BMC Med Genomics (2012) 1.29
Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network. J Clin Oncol (2012) 1.28
Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression. Mod Pathol (2014) 1.16
Translating cancer 'omics' to improved outcomes. Genome Res (2012) 1.07
Variants of uncertain significance in BRCA testing: evaluation of surgical decisions, risk perception, and cancer distress. Clin Genet (2013) 1.05
Awareness of cancer susceptibility genetic testing: the 2000, 2005, and 2010 National Health Interview Surveys. Am J Prev Med (2014) 1.01
Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico. Cancer (2014) 0.97
Clinical Application of Multigene Panels: Challenges of Next-Generation Counseling and Cancer Risk Management. Front Oncol (2015) 0.95
Epigenetics and the transition from acute to chronic pain. Pain Med (2012) 0.93
Citizens' perspectives on personalized medicine: a qualitative public deliberation study. Eur J Hum Genet (2013) 0.93
Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting. Cancer Control (2012) 0.93
Personalized medicine and access to health care: potential for inequitable access? Eur J Hum Genet (2012) 0.92
Pre-test genetic counseling services for hereditary breast and ovarian cancer delivered by non-genetics professionals in the state of Florida. Clin Genet (2014) 0.88
Next-Generation Testing for Cancer Risk: Perceptions, Experiences, and Needs Among Early Adopters in Community Healthcare Settings. Genet Test Mol Biomarkers (2015) 0.88
Development of a communication protocol for telephone disclosure of genetic test results for cancer predisposition. JMIR Res Protoc (2014) 0.83
Pharmacopuncture for cancer care: a systematic review. Evid Based Complement Alternat Med (2014) 0.83
Modes of delivery of genetic testing services and the uptake of cancer risk management strategies in BRCA1 and BRCA2 carriers. Clin Genet (2013) 0.82
A focus group study on breast cancer risk presentation: one format does not fit all. Eur J Hum Genet (2012) 0.82
Participation of low-income women in genetic cancer risk assessment and BRCA 1/2 testing: the experience of a safety-net institution. J Community Genet (2015) 0.81
Multiplex genetic cancer testing identifies pathogenic mutations in TP53 and CDH1 in a patient with bilateral breast and endometrial adenocarcinoma. BMC Med Genet (2013) 0.81
Predictive models for mutations in mismatch repair genes: implication for genetic counseling in developing countries. BMC Cancer (2012) 0.80
Impact of web-based case conferencing on cancer genetics training outcomes for community-based clinicians. J Cancer Educ (2012) 0.80
From observation to intervention: development of a psychoeducational intervention to increase uptake of BRCA genetic counseling among high-risk breast cancer survivors. J Cancer Educ (2014) 0.80
Characteristics associated with genetic counseling referral and BRCA1/2 testing among women in a large integrated health system. Genet Med (2014) 0.79
Benchmarking of Whole Exome Sequencing and Ad Hoc Designed Panels for Genetic Testing of Hereditary Cancer. Sci Rep (2017) 0.79
Implementation and outcomes of telephone disclosure of clinical BRCA1/2 test results. Patient Educ Couns (2013) 0.79
The future of clinical cancer genomics. Semin Oncol (2016) 0.79
Improving referral for genetic risk assessment in ovarian cancer using an electronic medical record system. Int J Gynecol Cancer (2014) 0.78
Hereditary cancer risk assessment: essential tools for a better approach. Hered Cancer Clin Pract (2013) 0.78
Hereditary cancer syndromes: opportunities and challenges. BMC Proc (2013) 0.78
Hypothesis on the Treatment of Gliomas with Acupuncture at the Primo Node Corresponding to Zusanli (ST 36). Med Acupunct (2015) 0.78
The role of the monoamine oxidase A gene in moderating the response to adversity and associated antisocial behavior: a review. Psychol Res Behav Manag (2014) 0.78
Prevalence and impact of founder mutations in hereditary breast cancer in Latin America. Genet Mol Biol (2014) 0.77
Identification, Evaluation, and Treatment of Patients with Hereditary Cancer Risk within the United States. ISRN Oncol (2013) 0.77
Age at diagnosis may trump family history in driving BRCA testing in a population of breast cancer patients. Cancer Epidemiol Biomarkers Prev (2013) 0.77
The Evolution of Epigenetics: From Prokaryotes to Humans and Its Biological Consequences. Genet Epigenet (2016) 0.76
Translation and adaptation of skin cancer genomic risk education materials for implementation in primary care. J Community Genet (2016) 0.76
An overview of epigenetics in nursing. Nurs Clin North Am (2013) 0.76
Hereditary cancer risk assessment: insights and perspectives for the Next-Generation Sequencing era. Genet Mol Biol (2016) 0.76
Challenges in managing genetic cancer risk: a long-term qualitative study of unaffected women carrying BRCA1/BRCA2 mutations. Genet Med (2014) 0.76
The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. NPJ Breast Cancer (2017) 0.75
Cancer classification in the genomic era: five contemporary problems. Hum Genomics (2015) 0.75
Use of BRCA Mutation Test in the U.S., 2004-2014. Am J Prev Med (2017) 0.75
The Brazilian Hereditary Cancer Network: historical aspects and challenges for clinical cancer genetics in the public health care system in Brazil. Genet Mol Biol (2016) 0.75
Hereditary Cancer: Example of a Public Health Approach to Ensure Population Health Benefits of Genetic Medicine. Healthcare (Basel) (2016) 0.75
Costs of genetic testing: Supporting Brazilian Public Policies for the incorporating of molecular diagnostic technologies. Genet Mol Biol (2015) 0.75
The front line of genomic translation. J Cancer Epidemiol (2012) 0.75
Applying public health screening criteria: how does universal newborn screening compare to universal tumor screening for Lynch syndrome in adults with colorectal cancer? J Genet Couns (2014) 0.75
Primary care providers' cancer genetic testing-related knowledge, attitudes, and communication behaviors: A systematic review and research agenda. J Gen Intern Med (2016) 0.75
Self-reported cancer family history is a useful tool for identification of individuals at risk of hereditary cancer predisposition syndrome at primary care centers in middle-income settings: a longitudinal study. Genet Mol Biol (2016) 0.75
Evaluation of psychosocial aspects in participants of cancer genetic counseling. Hered Cancer Clin Pract (2017) 0.75
Initial sequencing and analysis of the human genome. Nature (2001) 212.86
A haplotype map of the human genome. Nature (2005) 105.70
Exome sequencing identifies the cause of a mendelian disorder. Nat Genet (2009) 32.06
Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A (1971) 31.05
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 26.32
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst (1998) 22.10
Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst (1989) 19.87
Linkage of early-onset familial breast cancer to chromosome 17q21. Science (1990) 16.21
Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature (1973) 15.28
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology (2003) 14.67
A vision for the future of genomics research. Nature (2003) 14.06
Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell (1979) 14.05
A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature (1986) 13.96
Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease. Nat Genet (2003) 13.60
American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin (2007) 12.19
New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology (1999) 11.94
Hereditary colorectal cancer. N Engl J Med (2003) 11.86
Identification of FAP locus genes from chromosome 5q21. Science (1991) 11.41
Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (1990) 11.18
Clinical assessment incorporating a personal genome. Lancet (2010) 10.18
The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum (1991) 9.82
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet (2010) 9.72
The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med (2007) 9.48
Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med (2005) 9.39
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93
Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology (2000) 8.41
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet (2010) 8.41
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med (2002) 7.84
Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med (1999) 7.81
Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol (2002) 6.69
Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet (1998) 5.95
American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol (2003) 5.69
A decade's perspective on DNA sequencing technology. Nature (2011) 5.61
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2004) 5.38
Association of insurance with cancer care utilization and outcomes. CA Cancer J Clin (2007) 5.31
A breast cancer prediction model incorporating familial and personal risk factors. Stat Med (2004) 5.30
Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med (2005) 5.24
A process for measuring the quality of cancer care: the Quality Oncology Practice Initiative. J Clin Oncol (2005) 5.23
Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med (2006) 4.95
American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol (2010) 4.93
Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. JAMA (2005) 4.93
Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol (2009) 4.84
Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA (1997) 4.79
Health literacy and cancer communication. CA Cancer J Clin (2002) 4.66
Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med (2005) 4.66
Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. Lancet Oncol (2008) 4.49
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol (2002) 4.38
Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer (1994) 4.37
Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA (2006) 4.34
BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med (1997) 4.33
An agenda for personalized medicine. Nature (2009) 4.14
The "duty to warn" a patient's family members about hereditary disease risks. JAMA (2004) 4.13
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA (2006) 4.09
The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer (2004) 4.06
Personalized medicine in the era of genomics. JAMA (2007) 4.02
A TRANSMISSIBLE AVIAN NEOPLASM. (SARCOMA OF THE COMMON FOWL.). J Exp Med (1910) 3.99
Assessing women at high risk of breast cancer: a review of risk assessment models. J Natl Cancer Inst (2010) 3.94
Disclosure of individual genetic data to research participants: the debate reconsidered. Trends Genet (2010) 3.83
Cancer genomics: from discovery science to personalized medicine. Nat Med (2011) 3.66
EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med (2009) 3.57
Barriers to the provision of genetic services by primary care physicians: a systematic review of the literature. Genet Med (2003) 3.55
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol (2009) 3.51
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet (2000) 3.50
Genomic medicine--an updated primer. N Engl J Med (2010) 3.48
Detection of avian tumor virus-specific nucleotide sequences in avian cell DNAs (reassociation kinetics-RNA tumor viruses-gas antigen-Rous sarcoma virus, chick cells). Proc Natl Acad Sci U S A (1972) 3.28
Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet (2000) 3.12
Clinical implications of the cancer genome. J Clin Oncol (2010) 3.11
Genomic profiles for disease risk: predictive or premature? JAMA (2008) 3.07
Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA (2004) 2.99
Challenges in the clinical application of whole-genome sequencing. Lancet (2010) 2.92
Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA (2007) 2.91
Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila) (2010) 2.86
Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med (2008) 2.83
Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst (1997) 2.80
The $1,000 genome, the $100,000 analysis? Genome Med (2010) 2.79
A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. Am J Hum Genet (2010) 2.59
Influence of genetic discrimination perceptions and knowledge on cancer genetics referral practice among clinicians. Genet Med (2008) 2.53
Sharing BRCA1/2 test results with first-degree relatives: factors predicting who women tell. J Clin Oncol (2006) 2.53
Hereditary cancer predisposition syndromes. J Clin Oncol (2005) 2.49
Has the revolution arrived? Nature (2010) 2.47
PancPRO: risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol (2007) 2.45
Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw (2010) 2.45
Improvement in oncology practice performance through voluntary participation in the Quality Oncology Practice Initiative. J Clin Oncol (2008) 2.39
Clinical practice. Management of an inherited predisposition to breast cancer. N Engl J Med (2007) 2.37
Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome. JAMA (2010) 2.36
P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer (2000) 2.35
Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996. J Clin Oncol (1996) 2.32
Concise handbook of familial cancer susceptibility syndromes - second edition. J Natl Cancer Inst Monogr (2008) 2.29
Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol (2011) 2.17
Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. N Engl J Med (1998) 2.17
Confirmation of family cancer history reported in a population-based survey. J Natl Cancer Inst (2011) 2.13
Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol (2010) 2.12
Healthcare system factors and colorectal cancer screening. Am J Prev Med (2002) 2.11
All in the family: evaluation of the process and content of sisters' communication about BRCA1 and BRCA2 genetic test results. Am J Med Genet (2002) 2.05
Evaluation of a breast/ovarian cancer genetics referral screening tool in a mammography population. Genet Med (2009) 2.05
ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol (2009) 2.02
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med (2002) 7.84
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol (2010) 4.93
Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc Natl Acad Sci U S A (2008) 4.76
Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet (2007) 4.69
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA (2006) 4.34
Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet (2011) 3.91
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol (2008) 3.54
Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol (2005) 3.44
MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res (2006) 3.26
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2002) 3.25
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet (2009) 3.10
The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med (2009) 2.91
Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA (2007) 2.91
Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol (2002) 2.80
TGFBR1*6A and cancer risk: a meta-analysis of seven case-control studies. J Clin Oncol (2003) 2.68
Influence of genetic discrimination perceptions and knowledge on cancer genetics referral practice among clinicians. Genet Med (2008) 2.53
Hereditary cancer predisposition syndromes. J Clin Oncol (2005) 2.49
Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw (2010) 2.45
Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst (2006) 2.42
Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer (2006) 2.41
Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. J Clin Oncol (2012) 2.40
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
Clinical practice. Management of an inherited predisposition to breast cancer. N Engl J Med (2007) 2.37
Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. Ann Surg Oncol (2007) 2.19
Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res (2002) 2.16
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res (2003) 2.09
BLM heterozygosity and the risk of colorectal cancer. Science (2002) 2.03
Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? J Clin Oncol (2013) 2.03
Prevalence of BRCA mutations and founder effect in high-risk Hispanic families. Cancer Epidemiol Biomarkers Prev (2005) 2.00
Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev (2011) 1.99
Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol (2010) 1.98
Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns (2011) 1.92
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol (2007) 1.89
Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genet (2013) 1.88
Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat Genet (2013) 1.85
AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. Cancer Epidemiol Biomarkers Prev (2007) 1.75
Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science (2014) 1.74
Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk. JAMA (2008) 1.73
Genetic cancer risk assessment and counseling: recommendations of the national society of genetic counselors. J Genet Couns (2004) 1.69
Psychosocial predictors of BRCA counseling and testing decisions among urban African-American women. Cancer Epidemiol Biomarkers Prev (2002) 1.68
Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res (2010) 1.68
Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer. J Natl Cancer Inst (2004) 1.63
BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res (2004) 1.61
Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Arch Surg (2003) 1.57
Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet (2010) 1.56
Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. PLoS Genet (2013) 1.56
Prevention and management of hereditary breast cancer. J Clin Oncol (2005) 1.55
Description and pilot results from a novel method for evaluating return of incidental findings from next-generation sequencing technologies. Genet Med (2013) 1.55
Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer. Am J Surg Pathol (2003) 1.54
Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene. Proc Natl Acad Sci U S A (2009) 1.54
Analysis of genetic variation in Ashkenazi Jews by high density SNP genotyping. BMC Genet (2008) 1.53
Estrogen receptor genotypes and haplotypes associated with breast cancer risk. Cancer Res (2004) 1.52
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2011) 1.51
Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms. Am J Surg Pathol (2005) 1.49
Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer (2005) 1.48
Genetic/familial high-risk assessment: breast and ovarian, version 1.2014. J Natl Compr Canc Netw (2014) 1.48
Diagnosing hereditary colorectal cancer. Clin Colorectal Cancer (2010) 1.47
Genome-wide association studies of cancer: principles and potential utility. Oncology (Williston Park) (2010) 1.47
Genome-wide association studies of cancer. J Clin Oncol (2010) 1.45
Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol (2003) 1.43
TGFBR1*6A and cancer: a meta-analysis of 12 case-control studies. J Clin Oncol (2004) 1.42
Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma. Nat Med (2011) 1.42
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2010) 1.41
ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol (2006) 1.41
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res (2012) 1.38
BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol (2008) 1.36
Translating genomics in cancer care. J Natl Compr Canc Netw (2013) 1.35
Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer. Cancer Prev Res (Phila) (2010) 1.35
Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer (2011) 1.32
Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk. Cancer Res (2005) 1.29
Variants of the adiponectin and adiponectin receptor 1 genes and breast cancer risk. Cancer Res (2008) 1.28
Revealing the incidentalome when targeting the tumor genome. JAMA (2013) 1.27
Genetic analysis of the early natural history of epithelial ovarian carcinoma. PLoS One (2010) 1.25
Evidence for common ancestral origin of a recurring BRCA1 genomic rearrangement identified in high-risk Hispanic families. Cancer Epidemiol Biomarkers Prev (2007) 1.25
Cancer genomics and inherited risk. J Clin Oncol (2014) 1.24
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res (2011) 1.22
MSH6 germline mutations are rare in colorectal cancer families. Int J Cancer (2003) 1.21
Risks to relatives in genomic research: a duty to warn? Am J Bioeth (2012) 1.19
Susceptibility loci associated with prostate cancer progression and mortality. Clin Cancer Res (2010) 1.19
Results of a randomized study of telephone versus in-person breast cancer risk counseling. Patient Educ Couns (2006) 1.19
The role of prevention in oncology practice: results from a 2004 survey of American Society of Clinical Oncology members. J Clin Oncol (2006) 1.18
Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2012) 1.17
Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy? Breast Cancer Res Treat (2013) 1.16
Colorectal cancer risk in individuals with biallelic or monoallelic mutations of MYH. Int J Cancer (2005) 1.16
Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. Cancer (2003) 1.15
Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population. Hum Mol Genet (2005) 1.15
Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). PLoS One (2012) 1.13
The 6q22.33 locus and breast cancer susceptibility. Cancer Epidemiol Biomarkers Prev (2009) 1.13
Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol (2011) 1.12
Social-cognitive aspects of underserved Latinas preparing to undergo genetic cancer risk assessment for hereditary breast and ovarian cancer. Psychooncology (2008) 1.11